James Hutchinson

[Chris Humphries @cp_humphries]

Our trial protocol is out - first-in-human allogeneic macrophages for the treatment of paracetamol liver injury. Can they fill the gap between acetylcysteine and transplant? https://t.co/iLdzuEy0zb @EdinClinTox

[James Hutchinson @James_Hutc]

Proteolytic shedding of CD46 from human hepatocytes indicates liver stress: Heliyon https://t.co/u9IoV6X4E3

[Esteban Ballestar @eballestar]

Don't miss our collaborative study proposing combined therapy for #MultipleSclerosis Targeting #AhR w/ #DMF restores #tolerogenic #DendriticCells properties | A basis for new clinical trials @FedericoFonde @Eva_M_C @GTRecerca @CarrerasIJC @hgermanstrias
https://t.co/eMHGkMTxbs

[James Hutchinson @James_Hutc]

First Class Doctorate for Federico! ⁦@INsTRuCT_h2020⁩

[James Hutchinson @James_Hutc]

The August issue of Transplantation picked-up Dataset Restriction as a Research Highlight. Find the full article by Collin Z Jordan at https://t.co/vx21egv8yj

[James Hutchinson @James_Hutc]

Health implies homeostasis, whereas disease means dysregulation. It shouldn’t surprise us that disease markers are often more variably expressed in patients than controls @ExtraHorizon_ @INsTRuCT_h2020 @GGlehr @die_paloma
#melanoma #irAE

[James Hutchinson @James_Hutc]

Restriction also helps with intraclass heterogeneity. An unanticipated consequence of restriction is that disease biomarkers with a bimodal distribution in the positive class, such as might arise from multiple aetiologies, are findable.
#biomarkers #predictive_models #ROC_curve

[James Hutchinson @James_Hutc]

Combination cell therapy leads to clonal deletion of donor-specific T cells in kidney transplant recipients - eBioMedicine https://t.co/jce3ahAIhc

[James Hutchinson @James_Hutc]

https://t.co/Rv2ryW3JxG

[Transplantation @TransplantJrnl]

Social media and scientific publishing. Why it's important for authors and readers to follow articles from Transplantation and Transplantation Direct. Our editor @BaanCarla explains!

[James Hutchinson @James_Hutc]

IL-4+ iNKT cells are a mechanistically surprising subset in hepatic steatosis that certainly deserve more attention. Congratulations to Florian, Paul, Raphael and Giulia!

[Paloma Riquelme @die_paloma]

Promising new marker of early liver disease that links hepatocyte stress in fatty liver disease with iNKT cell activation in patients with MASLD:

Soluble CD46 as a diagnostic marker of hepatic steatosis https://t.co/6VxvEuL7aV

[James Hutchinson @James_Hutc]

Congratulations Maria for graduating Cum Laude! @INsTRuCT_h2020 👩🏻‍🎓

[James Hutchinson @James_Hutc]

Immune profiling of adipose tissue lymphocytes from patients with peritoneal carcinomatosis undergoing CRS-HIPEC leads to interesting new hypotheses. Good job, Julia! https://t.co/nE3KGqIBNX

[James Hutchinson @James_Hutc]

New article by Florian and Jordi - well done. Case report: Predictability of clinical response and rejection risk after immune checkpoint inhibition in liver transplantation https://t.co/zx5FGQ1x8j

[María Iglesias @Mar_mies]

The Extra project is looking for PhD candidates:
✅If you are willing to relocate to Barcelona
✅Have a background in translational Immunology & flow cytometry
✅ Are interested in the field of solid organ transplantation
Please check out the link (workpack DoC9) @Inmunocanruti

[James Hutchinson @James_Hutc]

exTra is a spin-off from INsTRuCT focused on apoptotic cell therapy in solid organ transplantation. If you’re looking for a PhD project with translational relevance, apply to exTra before 15th August, 2023.

[INsTRuCT @INsTRuCT_h2020]

exTra opened a call for 11 MSCA PhD Student positions to train in Basic and Translational Immunology. Projects in DE, AT, UK, NL and ES. Apply through EURAXESS. https://t.co/Tq2iUTGxVk

[INsTRuCT @INsTRuCT_h2020]

Our new article about dataset restriction was released today as a #preprint on @researchsquare: https://t.co/EQJZQXlJAS